3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Genitourinary
1
Conditions
Motor Activity
4
Prostatic Neoplasms
3
Malnutrition
3
Stomach Neoplasms
2
Frailty
2
Breast Neoplasms
2
Urologic Neoplasms
1
Smoking
1
Risk Reduction Behavior
1
Postoperative Complications
1
Patient Preference
1
Obesity
1
Neoplasms
1
Hematologic Neoplasms
1
Fatigue
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Depression
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms, Male
1
Alcohol Drinking
1
Interventions
pembrolizumab
3
atezolizumab
2
Sugammadex
2
Saline Solution
2
Paclitaxel
2
Neostigmine
2
Gemcitabine
2
Cetuximab
2
zidovudine 5'-monophosphate-mannose-albumin conjugate
1
tislelizumab
1
testosterone 17 beta-cypionate
1
temsirolimus
1
relatlimab
1
poly ICLC
1
lenvatinib
1
galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20
1
delta 24-sterol reductase
1
daratumumab
1
cabozantinib
1
abemaciclib
1
Zoledronic Acid
1
Water
1
Valproic Acid
1
Urinary Diversion
1
Ultrasonography
1
Trastuzumab
1
Tomography, Optical Coherence
1
Tissue Banks
1
Therapeutics
1
Testosterone Propionate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Urologic Neoplasms
×
Nutritional Support
×
Clear all
NCT04088968
2024-03-22
STRONG-CS
Bispebjerg Hospital
Phase NA
Unknown
100 enrolled